Mediwound L receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mediwound Ltd (MDWD)
Track the Mediwound share price today and view real-time MDWD share price data, including charts, technicals, and key financials. View the MDWD premarket stock price ahead of the market session or assess the after hours quote. Explore MDWD stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the Mediwound Stock Price Today?
The Mediwound stock price today is 13.290.
What Is the Stock Symbol for Mediwound?
The stock symbol for Mediwound is ""MDWD.""
What Stock Exchange Does Mediwound Trade On?
Mediwound is listed and trades on the NASDAQ stock exchange.
Is Mediwound a Good Stock to Buy?
Determining whether Mediwound or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDWD quote. (ISIN: IL0011316309)
What Is the Mediwound Stock Price Today?
The Mediwound stock price today is 13.290.
What Is the Stock Symbol for Mediwound?
The stock symbol for Mediwound is ""MDWD.""
What Stock Exchange Does Mediwound Trade On?
Mediwound is listed and trades on the NASDAQ stock exchange.
Is Mediwound a Good Stock to Buy?
Determining whether Mediwound or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDWD quote. (ISIN: IL0011316309)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.030
13.410
52 wk Range
12.520
20.300
MDWD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.03013.410
52 wk Range
12.52020.300
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MDWD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
29.833
Upside
+124.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Form 6K MediWound Ltd. For: 6 May- Investing.com
- Mediwound L receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 6K Mediwound Ltd For: 27 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 29.833
(+124.48% Upside)
Mediwound Ltd Earnings Call Summary for Q2/2026
- Q2 revenue of $3.1M beat forecast by 7.3% but fell 45.6% YoY due to timing of BARDA-funded development revenue; shares rose 1.87% to $14.17.
- Company reaffirmed FY2026 revenue guidance of $24M-$26M, weighted to H2, driven by Vericel MSA, government programs, and NexoBrid commercial sales.
- EscharEx phase III trial at 90% site activation, targeting enrollment completion by Q1 2027; updated peak U.S. sales potential raised to $1.05B from $800M.
- Operating loss widened to $9.5M from $5.7M YoY as R&D spending jumped to $5.9M; cash declined to $36M from $54M at year-end 2025 amid burn rate.
- NexoBrid posted strongest quarter since Vericel launch; EMA-requested manufacturing modifications expected Q4 2026, with expanded facility supply in H2 2027.
Last Updated: 14/08/2026, 12:00 am
Read Full TranscriptEarnings
Latest Release
13/08/2026
EPS / Forecast
-0.77 / -0.74
Revenue / Forecast
3.09M / 2.89M
Compare MDWD to Peers and Sector
Metrics to compare | MDWD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDWDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.5x | −2.1x | −0.4x | |
PEG Ratio | −0.58 | −0.06 | 0.00 | |
Price/Book | 4.8x | 1.5x | 2.6x | |
Price / LTM Sales | 14.5x | 2.4x | 3.0x | |
Upside (Analyst Target) | 125.7% | 27.5% | 47.5% | |
Fair Value Upside | Unlock | 8.4% | 6.7% | Unlock |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Mediwound (MDWD) Stock Price Today?
The Mediwound stock price today is 13.290 USD.
What Stock Exchange Does Mediwound Trade On?
Mediwound is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Mediwound?
The stock symbol for Mediwound is "MDWD."
What Is the Mediwound Market Cap?
As of today, Mediwound market cap is 171.580M USD.
What Is Mediwound's Earnings Per Share (TTM)?
The Mediwound EPS (TTM) is -2.246.
When Is the Next Mediwound Earnings Date?
Mediwound will release its next earnings report on 17/11/2026.
From a Technical Analysis Perspective, Is MDWD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Mediwound Stock Split?
Mediwound has split 1 times.
How Many Employees Does Mediwound Have?
Mediwound has 121 employees.
What is the current trading status of Mediwound (MDWD)?
As of 07/09/2026, Mediwound (MDWD) is trading at a price of 13.290 USD, with a previous close of 13.210 USD. The stock has fluctuated within a day range of 13.030 USD to 13.410 USD, while its 52-week range spans from 12.520 USD to 20.300 USD.
What Is Mediwound (MDWD) Price Target According to Analysts?
The average 12-month price target for Mediwound is 29.833 USD, with a high estimate of 36 USD and a low estimate of 22 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +124.48% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.